Dataset Information

Urodynamic outcomes of tamsulosin in the treatment of primary bladder neck obstruction in men.

ABSTRACT: Introduction:Alpha blockers are widely used in the treatment of primary bladder neck obstruction; however, evidence for objective urodynamic efficacy is scarce. We studied the effect of the uroselective ?1-blocker tamsulosin on urodynamic parameters in male patients with type I primary bladder neck obstruction. Methods:A single center prospective observational study was carried out from July 2013 to February 2015. Male patients (18-50 years) with type 1 primary bladder neck obstruction were recruited. Selected patients were started on tablet tamsulosin 0.4 mg once daily for 3 months. International prostate symptom score (IPSS), uroflow and urodynamic studies were done pre- and post-treatment. Primary outcome was decreased in minimum detrusor pressure at maximum flow rate by 15%. Wilcoxon-matched pair signed-rank test was used. Results:Of 39 patients recruited, 21 patients completed the follow-up as per protocol and were analyzed. Mean age was 41 years. 57% patients achieved the primary outcome (median detrusor pressure pre- and post-treatment were 71 and 56 cm of water, P < 0.001). Similarly, median values for bladder outlet obstruction index (BOOI) and IPSS decreased from 59 to 38 (P < 0.001) and 22 to 12 (P < 0.001), respectively. Median maximum flow rate increased from 8 to 10 ml (P = 0.05). Pretreatment BOOI of >60 was associated with poor outcomes. Conclusions:Tamsulosin 0.4 mg once a day is effective in reducing bladder outlet obstruction on pressure flow studies in patients with primary bladder neck obstruction type 1.

SUBMITTER: Sudrania MK

PROVIDER: S-EPMC5769247 | biostudies-literature | 2018 Jan-Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Urodynamic outcomes of tamsulosin in the treatment of primary bladder neck obstruction in men.

Sudrania Manoj K MK Dangi Anuj Deep AD Kumar Santosh S Kumar Barath B Kekre Nitin S NS

Indian journal of urology : IJU : journal of the Urological Society of India 20180101 1

<h4>Introduction</h4>Alpha blockers are widely used in the treatment of primary bladder neck obstruction; however, evidence for objective urodynamic efficacy is scarce. We studied the effect of the uroselective α1-blocker tamsulosin on urodynamic parameters in male patients with type I primary bladder neck obstruction.<h4>Methods</h4>A single center prospective observational study was carried out from July 2013 to February 2015. Male patients (18-50 years) with type 1 primary bladder neck obstru ...[more]

PMID: 29343910

Similar Datasets

Project description:IntroductionMATCH was a randomized, double-blind, placebo-controlled study enrolling Japanese and Korean men aged???40 years who still had overactive bladder (OAB) symptoms while receiving tamsulosin. After a 4-week single-blind screening period in which patients received placebo and tamsulosin, patients were randomized to mirabegron 50 mg?+?tamsulosin or placebo?+?tamsulosin for 12 weeks (n?=?568). This post hoc analysis investigated the proportion of treatment responders for each treatment group and for subgroups stratified by age based on voiding diaries and patient-reported outcomes (PROs).MethodsResponders were defined as those achieving normalization or clinically meaningful improvements in efficacy, or clinically important differences in PROs [??10-point improvement in OAB questionnaire (OAB-q) symptom bother or total health-related quality of life (HRQoL) subscales at end of treatment (EoT; minimally important difference [MID]) or OAB symptom score (OABSS) total score decreased by???3 points at EoT [minimally clinically important change (MCIC)]].ResultsAt EoT, micturition frequency normalization was achieved by 30.7% of tamsulosin?+?mirabegron patients and 18.6% of tamsulosin?+?placebo patients. Normalization of urgency and incontinence was 19.1% and 60.7% for tamsulosin?+?mirabegron and 18.2% and 60.0% for tamsulosin?+?placebo. Normalization of OAB symptoms based on OABSS was 17.1% for tamsulosin?+?mirabegron and 14.5% for tamsulosin?+?placebo. Higher proportions of patients in the mirabegron add-on group versus the placebo group reported clinically meaningful improvements in micturitions, urgency, and incontinence and in MCIC for OABSS and MID for the OAB-q subscales. Double- and triple-responder findings were as predicted by the results of single-responder analyses. These results were mirrored in the age groups using cut-offs of 65 and 75 years.ConclusionMirabegron therapy added on to tamsulosin resulted in a higher frequency of responders in terms of normalization (e.g., micturition frequency normalization), clinically meaningful improvements in efficacy (e.g.,???50% decrease in urgency), and minimally important changes in PROs (e.g., MCIC in OABSS).Trial registrationClinicalTrials.gov identifier, NCT02656173.

Dataset Information

Urodynamic outcomes of tamsulosin in the treatment of primary bladder neck obstruction in men.

Publications

Urodynamic outcomes of tamsulosin in the treatment of primary bladder neck obstruction in men.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure